UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 266

Sortiert nach

129 Regional Experience of Cemiplimab, in Locally advanced and stage IV Head and Neck Cutaneous Squamous Cell Carcinomas

Radiotherapy and oncology, 2024-03, Vol.192, p.S149-S151

2024

Volltextzugriff (PDF)

Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis

Journal of the American Academy of Dermatology, 2024-06

2024

Volltextzugriff (PDF)

Advanced cutaneous squamous cell carcinoma: Impact of age on the safety and efficacy of cemiplimab and the prognostic significance of blood biomarkers

Journal of geriatric oncology, 2024-06, Vol.15 (5), p.101789-101789, Article 101789

2024

Volltextzugriff (PDF)

Posterior Uveitis Associated with Cemiplimab

Ocular immunology and inflammation, 2022-07, Vol.30 (5), p.1211-1213

2022

Volltextzugriff (PDF)

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

Cancers, 2020-03, Vol.12 (3), p.738

2020

Volltextzugriff (PDF)

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

Journal for immunotherapy of cancer, 2019-10, Vol.7 (1), p.278-278, Article 278

2019

Volltextzugriff (PDF)

2018 FDA drug approvals

Nature reviews. Drug discovery, 2019-02, Vol.18 (2), p.85-89

Mullard, Asher

2019

Volltextzugriff (PDF)

Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab)

Frontiers in immunology, 2024-07, Vol.15, p.1408667

2024

Volltextzugriff (PDF)

This Month in JAAD International: July 2024

Journal of the American Academy of Dermatology, 2024-07, Vol.91 (1), p.28-28

Kantor, Jonathan

2024

Volltextzugriff (PDF)

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023

European journal of cancer (1990), 2023-11, Vol.193, p.113252-113252, Article 113252

2023

Volltextzugriff (PDF)

PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer

Gynecologic oncology, 2020-11, Vol.159 (2), p.322-328

2020

Volltextzugriff (PDF)

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial

Lung cancer (Amsterdam, Netherlands), 2024-07, Vol.193, p.107821, Article 107821

2024

Volltextzugriff (PDF)

Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy

Frontiers in oncology, 2021-11, Vol.11, p.686308-686308

2021

Volltextzugriff (PDF)

Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma

Future oncology (London, England), 2021-02, Vol.17 (5), p.611-627

2021

Volltextzugriff (PDF)

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review

Oncotarget, 2021-05, Vol.12 (11), p.1116-1121

2021

Volltextzugriff (PDF)

Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response

Journal of cutaneous pathology, 2021-05, Vol.48 (5), p.674-679

2021

Volltextzugriff (PDF)

The efficacy and safety of cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: A comparative analysis of retrospective studies versus prospective studies

Dermatologic therapy, 2022-09, Vol.35 (9), p.n/a

2022

Volltextzugriff (PDF)

Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes

Ocular immunology and inflammation, 2021-01, Vol.29 (1), p.203-211

2021

Volltextzugriff (PDF)

Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma

Expert review of clinical pharmacology, 2019-10, Vol.12 (10), p.947-951

2019

Volltextzugriff (PDF)

Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

European journal of cancer (1990), 2021-11, Vol.157, p.250-258

2021

Volltextzugriff (PDF)

Onset of psoriasis with immune checkpoint inhibitor therapy: A systematic review

Journal of the American Academy of Dermatology, 2024-02, Vol.90 (2), p.392-395

2024

Volltextzugriff (PDF)

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort

Lung cancer (Amsterdam, Netherlands), 2021-05, Vol.155, p.151-155

2021

Volltextzugriff (PDF)

Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study

Clinical genitourinary cancer, 2024-06, Vol.22 (3), p.102074-102074, Article 102074

2024

Volltextzugriff (PDF)

Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony‐Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

The oncologist (Dayton, Ohio), 2021-09, Vol.26 (9), p.e1508-e1513

2021

Volltextzugriff (PDF)

1 – 25 von 266

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(183)
Mit Volltextzugriff
(189)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

129 Regional Experience of Cemiplimab, in Locally advanced and stage IV Head and Neck Cutaneous Squamous Cell Carcinomas

Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis

European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment

Advanced cutaneous squamous cell carcinoma: Impact of age on the safety and efficacy of cemiplimab and the prognostic significance of blood biomarkers

Posterior Uveitis Associated with Cemiplimab

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

2018 FDA drug approvals

Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab)

This Month in JAAD International: July 2024

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023

PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial

Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy

Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma

Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review

Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response

The efficacy and safety of cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: A comparative analysis of retrospective studies versus prospective studies

Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes

Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma

Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

Onset of psoriasis with immune checkpoint inhibitor therapy: A systematic review

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort

Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study

Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony‐Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Suchergebnisse filtern